Target intelligence / Profile preview

Hantavirus glycoprotein Gc (Gc)

Target
Gc
Molecular classification
Viral envelope protein, Class II fusion protein, Other
01

Overview

Hantavirus glycoprotein Gc is a viral envelope protein essential for virus entry into host cells and a major target for the immune response. It is encoded by the M segment of the hantavirus genome and forms a heterodimer with glycoprotein Gn, assembling into tetrameric spikes that create a surface lattice on the virus[1][5][9]. Gc is classified as a **class II fusion protein**, structurally and functionally analogous to fusion proteins found in other enveloped viruses. During infection, Gn/Gc spikes engage host cell receptors, and upon endocytosis and acidification of the endosome, Gc undergoes an irreversible conformational change to mediate fusion between the viral envelope and the endosomal membrane, allowing viral genome release into the cytoplasm[3][6][8]. Gc is the **membrane fusion effector** and the principal target of neutralizing antibodies, making it a candidate for vaccines and antiviral drug development[1][3][8]. The structure of Gc has been resolved in its post-fusion trimer conformation, and its functional regions offer potential targets for membrane fusion inhibitors and antibody therapies[8]. There are currently no approved drugs that specifically target Gc, but research efforts are exploring antivirals that disrupt its conformational changes and monoclonal antibodies designed to neutralize its activity[8][9].

Other names
Glycoprotein CGc glycoproteinenvelope glycoprotein Gchantavirus Gc
02

Mechanism of action

Inhibition of the class II membrane fusion activity, preventing viral envelope fusion with host endosomal membrane Neutralization via binding and blocking conformational changes essential for fusion

03

Biological functions

Viral entry (mediates fusion of viral and host cell membranes)Virion assembly (partners with Gn to form surface spikes)Immune system evasion (target of neutralizing antibodies)Virus budding (via spikes and membrane interactions)
04

Disease associations

Infection (hantavirus-caused diseases: hemorrhagic fever with renal syndrome [HFRS], hantavirus pulmonary syndrome [HPS])
05

Safety considerations

Vaccine targeting risks include potential antibody-dependent enhancement (ADE) and immunopathologyRapid viral mutation may confer immune escape
06

Interacting drugs

Membrane fusion inhibitors (investigational; specific drugs not established)

1 more in the full profile.

07

Biomarkers

Presence or level of anti-Gc antibodies (for infection diagnosis or vaccine efficacy monitoring)

Beyond the preview

Go deeper on Hantavirus glycoprotein Gc (Gc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hantavirus glycoprotein Gc (Gc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call